electroCore grew revenue 27% in 2025, projects 30% growth in 2026 despite a larger net loss.

electroCore reported strong 2025 financial results with $32 million in annual revenue, a 27% year-over-year increase, driven by growth in VA channel prescriptions and wellness product sales. The company ended the year with a net loss of $14 million, up from $11.9 million, due to rising SG&A expenses, but improved gross margins to 87%. Leadership changes include CEO Daniel Goldberger’s retirement effective April 1, 2026, with Joshua Lev named interim President and CFO and Michael Fox joining as COO. The company projects 30% revenue growth in 2026, supported by a soft launch of Quell Relief (OTC), continued VA market expansion, and progress toward Kaiser formulary inclusion.